HER2-positive disseminated gastric and gastro-oesophageal junction adenocarcinoma: forecast, clinical course, treatment

HER2-positive disseminated gastric and gastro-oesophageal junction adenocarcinoma: forecast, clinical course, treatment

The main method of treatment patients with disseminated gastric cancer is drug therapy. Trastuzumab has proven its efficacy in therapyHER2-positive gastric cancer in combination with chemotherapy. In patients with advanced gastric or gastro-oesophageal junction cancer, addition of trastuzumab to che...

Full description

Bibliographic Details
Main Author:	N S Besova
Format:	Article
Language:	Russian
Published:	IP Habib O.N. 2014-09-01
Series:	Современная онкология
Subjects:	her2-positive gastric and gastro-oesophageal junction cancer her2-status trastuzumab target therapy
Online Access:	https://modernonco.orscience.ru/1815-1434/article/view/26958

Similar Items

Targeted and Immunotherapy Approaches in HER2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma: A New Era
by: Maluki Radford, et al.
Published: (2023-08-01)

Peri-operative Chemotherapy in Patients with Oesophageal and Gastro-oesophageal Junction Cancer – Three Years of Experience
by: Z. Pechačová, et al.
Published: (2013-01-01)

EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group
by: Anna Dorothea Wagner, et al.
Published: (2019-05-01)

MicroRNAs as biomarkers for trastuzumab-based therapy in HER2-positive advanced oesophago-gastric cancer patients
by: Hazel Lote, et al.
Published: (2023-11-01)

Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials
by: Francisco Cezar Aquino de Moraes, et al.
Published: (2024-02-01)

Results of the use of trastuzumab combined with different chemotherapy regimens in first-line treatment of HER2-positive disseminated gastric cancer
by: N. S. Besova, et al.
Published: (2019-06-01)

Combined Therapy of Locally Advanced Oesophageal and Gastro–Oesophageal Junction Adenocarcinomas: State of the Art and Aspects of Predictive Factors
by: Milan Vošmik, et al.
Published: (2021-09-01)

HER 2 Expression in Gastric and Gastro-esophageal Junction (GEJ) Adenocarcinomas
by: Indu Rajagopal, et al.
Published: (2015-03-01)

Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial
by: Tianshu Liu, et al.
Published: (2019-06-01)

Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?
by: Angela Dalia Ricci, et al.
Published: (2021-04-01)

Challenges and future of HER2-positive gastric cancer therapy
by: Chenzhe Ma, et al.
Published: (2023-01-01)

Aggressive HER2-Positive Gastric Cancer in a Young Patient, Refractory in Trastuzumab and Progressive with Trastuzumab-Emtansine Treatment
by: Vildana Goga Çmega, et al.
Published: (2024-03-01)

Real‐world clinical outcomes of the combination of anti‐PD‐1 antibody, trastuzumab, and chemotherapy for HER2‐positive gastric/gastroesophageal junction cancer
by: Ju Yang, et al.
Published: (2023-04-01)

Emerging Targeted Therapies for HER2 Positive Gastric Cancer That Can Overcome Trastuzumab Resistance
by: Seiichiro Mitani, et al.
Published: (2020-02-01)

Significant effect of posterior line treatment of HER2 positive advanced gastric cancer: A case report
by: Xiaoting Ma, et al.
Published: (2024-04-01)

Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2 + Advanced Gastric Cancer: A Retrospective Study
by: Tong G, et al.
Published: (2020-04-01)

Dual HER2 blockade with lapatinib and trastuzumab in combination with chemotherapy in metastatic gastroesophageal adenocarcinoma
by: E. Von Cheong, et al.
Published: (2021-04-01)

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
by: Hamid Maadi, et al.
Published: (2018-03-01)

HER2-Positive Gastric Cancer and Antibody Treatment: State of the Art and Future Developments
by: Magdalena K. Scheck, et al.
Published: (2024-03-01)

HER2 Inhibition in Gastric Cancer—Novel Therapeutic Approaches for an Established Target
by: Caroline Fong, et al.
Published: (2022-08-01)

Efficacy and safety of zolbetuximab for first-line treatment of advanced Claudin 18. 2-positive gastric or gastro-esophageal junction adenocarcinoma: a systematic review and meta-analysis of randomized controlled trials
by: Zhanpeng Liang, et al.
Published: (2023-10-01)

Identifying HER2 from serum‐derived exosomes in advanced gastric cancer as a promising biomarker for assessing tissue HER2 status and predicting the efficacy of trastuzumab‐based therapy
by: Qian Li, et al.
Published: (2023-02-01)

Current issues of gastro-oesophageal reflux disease surgical treatment in children
by: Nurlan Nurkinovich Akhparov, et al.
Published: (2021-01-01)

Laparo-endoscopic transgastric resection of gastric gastrointestinal stromal tumor located near the gastro-oesophageal junction with hiatus hernia repair
by: Richa Mishra, et al.
Published: (2022-01-01)

Study of HER2 Expression and its Relation to Tumor Characteristics among Gastric Adenocarcinoma Patients of Firoozgar Hospital, Tehran, Iran; in 2010 and 2011
by: Ali Basi, et al.
Published: (2012-10-01)

Study of HER2 Expression and its Relation to Tumor Characteristics among Gastric Adenocarcinoma Patients of Firoozgar Hospital, Tehran, Iran; in 2010 and 2011
by: Ali Basi, et al.
Published: (2015-10-01)

Long-term survival after multidisciplinary treatments for HER2-positive advanced gastric cancer with multiple liver and lung metastases
by: Satoshi Yoshioka, et al.
Published: (2023-08-01)

Expression of Her2-Neu in Primary Gastric and Gastroesophageal Adenocarcinoma: An Experience from a Tertiary Center in South India
by: Aditi Damle, et al.

HER2 expression, gene amplification and chromosome 17 copy number in primary pancreatic adenocarcinoma, matastatic lymph node and metastasis
by: S. Boccardo, et al.
Published: (2011-01-01)

Factors Affecting the Prevalence of Gastro-oesophageal Reflux in Childhood Corrosive Oesophageal Strictures
by: Serdar H. İskit, et al.
Published: (2014-06-01)

The Durable Effect of Pyrotinib Plus Trastuzumab and Chemotherapy in HER2-Positive Gastric Cancer With Brain Metastases: A Case Report and Literature Review
by: Xinwei Wang, et al.
Published: (2022-07-01)

Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
by: Volkmar Müller, et al.
Published: (2018-03-01)

Evolving Treatment Landscape of <i>HER2</i>-mutant Non-Small Cell Lung Cancer: Trastuzumab Deruxtecan and Beyond
by: Ioannis A. Vathiotis, et al.
Published: (2023-02-01)

The effect of specimen processing time on HER2 expression in gastric cancer and esophagogastric junction cancer: a single-center retrospective observational study
by: Yoshitomo Yanagimoto, et al.
Published: (2023-07-01)

How I treat HER2-low advanced breast cancer
by: Ilana Schlam, et al.
Published: (2023-02-01)

Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective
by: Michelle Bradbury, et al.
Published: (2023-12-01)

The Effect of Omeprazol in the Treatment of Laryngeal Manifestations of Gastro-oesophageal Reflux
by: Oday Abdelrahman Al-beiruty, et al.
Published: (2008-07-01)

Case Report: Durable Clinical Response to Third-Line Pyrotinib After Resistance to Trastuzumab in a Gastric Cancer Patient
by: Junyi Wu, et al.
Published: (2022-01-01)

The effect of combinated treatment of a metastatic HER2-positive stomach cancer
by: R A Khvastunov, et al.
Published: (2014-12-01)

Cure Is Possible: Extensively Metastatic HER2-Positive Gastric Carcinoma with 5 years of Complete Remission after Therapy with the FLOT Regimen and Trastuzumab
by: Sebastian Schade, et al.
Published: (2022-02-01)